Immunic Q3 Loss Widens to $42.3M as ENSURE Data Nears

Immunic, Inc. (Nasdaq: IMUX) reported on 13 November 2026 a third-quarter net loss of approximately $42.3 million, or $0.99 per basic and diluted share, against a $25.6 million loss in the same quarter of 2025, while holding $132.0 million in cash and cash equivalents. The company said top-line data from its twin Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis remain on track for December 2026.

Context — why the December ENSURE readout defines Immunic's next two years

The widening loss is not a surprise in isolation. Immunic is a clinical-stage company with no approved product, so its income statement reflects spending, not sales. What changed is the composition of that spending: the company is now paying to prepare a regulatory filing and a commercial launch before it knows whether its lead asset works.

Immunic's own comparable frames the shift. Research and development expenses rose to $23.9 million in the quarter from $20.0 million a year earlier, and general and administrative expenses jumped to $19.4 million from $6.0 million. The G&A increase alone, $13.4 million, is larger than the entire G&A base of the prior-year quarter.

The company attributed most of that G&A jump to personnel costs, including $9.7 million of non-cash stock compensation primarily tied to a separation agreement. That is a one-time-looking charge rather than a run-rate signal, but it lands in the same quarter the company is staffing up for launch.

Separately, R&D moved in two directions. NDA readiness activities added $2.9 million and vidofludimus calcium drug supply added $1.4 million, while the ENSURE trials themselves fell $1.8 million and the CALLIPER trial fell $1.0 million as those studies matured. Immunic is shifting from running trials to preparing to sell.

The catalyst chain is short and dated. The company said ENSURE top-line data are expected in December 2026. A positive result would trigger a planned NDA submission in the United States in mid-2027, with a targeted potential approval date in 2028.

Data — what the numbers show

The clearest way to read the quarter is against the prior-year period the company itself disclosed.

Metric (Q3)	2026	2025
Net loss	$42.3M	$25.6M
Net loss per share	$0.99	$1.32
R&D expense	$23.9M	$20.0M
G&A expense	$19.4M	$6.0M
Interest income	$1.1M	$0.4M
Weighted-average shares	42,797,370	19,389,776

The per-share loss narrowed even as the absolute loss grew, because the share count more than doubled. Immunic's February 2026 private placement lifted weighted-average shares outstanding to roughly 42.8 million from 19.4 million, and the same financing explains the rise in interest income to $1.1 million from $0.4 million on a higher average cash balance.

For the nine months ended 30 September 2026, the net loss was approximately $109.0 million, or $2.83 per share, versus $77.9 million, or $5.45 per share, a year earlier. Total operating expenses were $111.9 million across the nine months, including $25.2 million of non-cash charges.

Cash of $132.0 million, the company said, is expected to fund operations into late 2027. That runway extends past the December 2026 ENSURE readout and past the planned mid-2027 NDA submission, but not past the targeted 2028 approval date.

Analysis — what it means for IMUX holders and the MS sector

The runway math is the central tension. Immunic expects $132.0 million to carry it into late 2027, yet the company is simultaneously funding NDA readiness, drug supply, a new Phase 3 PROTECT-MS trial in progressive MS, and two new C-suite roles. Any of those can pull the cash-out date forward.

Immunic's own risk disclosure names this directly, flagging the risk that cash and cash equivalents may be insufficient to fund operations for the period anticipated, including due to changes to its operating plan, and its need to raise additional capital. For a company with no revenue, that means dilution risk sits between the December data and any approval.

The progressive MS program is the second exposure. Immunic said initiation of the Phase 3 PROTECT-MS trial is ongoing, with first-patient-enrolled expected in the first half of 2027, informed by Phase 2 CALLIPER data. That program spends money before the relapsing MS program has produced a regulatory answer.

The counter-argument deserves weight. The company disclosed that only 6.5% of CALLIPER patients discontinued through the 27 January 2026 data cutoff, with a tolerability profile that appeared consistent with the double-blind period. Tolerability is a genuine commercial differentiator in oral MS therapy, and it is one of the few datapoints that does not depend on the ENSURE readout.

Immunic also cautioned that several supporting findings come from open-label, post-hoc, or preclinical analyses. The company stated that its proposed novel statistical methods have not been validated or accepted by regulatory authorities, and that the clinical relevance of its preclinical Nurr1 findings has not been established.

Positioning around IMUX is therefore binary and event-driven. Holders are effectively long a December data readout, and the stock's reaction will be set by ENSURE endpoints rather than by this income statement.

Outlook — what to watch next

Three dated catalysts sit ahead. First, ENSURE-1 and ENSURE-2 top-line data are expected in December 2026. Second, Immunic plans an NDA submission in the United States in mid-2027 if those results are positive. Third, first-patient-enrolled in the Phase 3 PROTECT-MS trial in progressive MS is expected in the first half of 2027.

On the pipeline side, the company said IMU-381 remains in preclinical testing with lead candidate identification ongoing. No timeline was given for that program.

The report does not disclose ENSURE-1 and ENSURE-2 primary endpoint definitions, statistical powering, or the specific disability measures that will determine success. Investors will have to wait for the December readout to see how the trials define a win.

Cash is the other line to watch. Immunic guided to a runway into late 2027, and any update that shortens that window, or any financing announcement, would change the dilution picture before the NDA decision.

Frequently Asked Questions

Why did Immunic's net loss widen in Q3 2026?

The loss grew to $42.3 million from $25.6 million a year earlier, driven mainly by a $13.4 million jump in general and administrative expenses. Immunic attributed $11.0 million of that to personnel costs, including $9.7 million of non-cash stock compensation primarily related to a separation agreement. R&D also rose $3.9 million on NDA readiness and drug supply spending.

How long will Immunic's cash last?

Immunic reported $132.0 million in cash and cash equivalents as of 30 September 2026 and said that, based on its current operating plan, the funds should be sufficient to fund operations into late 2027. The company also disclosed the risk that its cash may be insufficient for the anticipated period and that it may need to raise additional capital.

What is vidofludimus calcium and has it been approved?

Vidofludimus calcium (IMU-838) is Immunic's lead investigational oral therapy, being tested in Phase 3 trials in relapsing multiple sclerosis. The company stated it has not been approved or authorized by the FDA, the EMA, or any other regulatory authority for any indication in any jurisdiction, and that its safety and efficacy have not been established.

Bottom Line

Immunic's widening loss is a launch-readiness bill, and the December 2026 ENSURE data decide whether it was worth paying.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.